FrancophonIA/ELRC3.0 huggingface dataset:
English: PREZISTA should be discontinued immediately if signs or symptoms of severe skin reactions develop.
Estonian: Raskete nahareaktsioonide nähtude ja sümptomite tekkel tuleb PREZISTA kasutamine otsekohe lõpetada.
English: The maraviroc dose should be 150 mg twice daily when co-administered with PREZISTA with low dose ritonavir.
Estonian: Maraviroki annus manustamisel koos PREZISTA ning ritonaviiri väikese annusega on 150 mg kaks korda ööpäevas.
English: - ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - elbasvir/grazoprevir - cisapride - dapoxetine - domperidone - naloxegol - lurasidone, pimozide, quetiapine, sertindole (see section 4.5) - triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
Estonian: Need toimeaineid hõlmavad järgmisi ravimeid: - alfusosiin; - amiodaroon, bepridiil, dronedaroon, ivabradiin, kinidiin, ranolasiin; - astemisool, terfenadiin; - kolhitsiin, kui seda kasutatakse neeru- ja/või maksakahjustusega patsientidel (vt lõik 4.5); - tungaltera derivaadid (nt dihüdroergotamiin, ergometriin, ergotamiin, metüülergonoviin); - elbasviir/grasopreviir; - tsisapriid; - dapoksetiin; - domperidoon; - naloksegool; - lurasidoon, pimosiid, kvetiapiin, sertindool (vt lõik 4.5); - triasolaam, suukaudne midasolaam (vt lõik 4.5 parenteraalselt manustatava midasolaami ettevaatusabinõud); - sildenafiil - kui seda kasutatakse pulmonaalse arteriaalse hüpertensiooni raviks, avanafiil; - simvastatiin, lovastatiin, lomitapiid (vt lõik 4.5); - dabigatraan, tikagreloor (vt lõik 4.5).
English: Clinical monitoring is recommended when co-administering boosted PREZISTA with these analgesics.
Estonian: Võimendatud PREZISTA samaaegsel manustamisel nende analgeetikumidega on soovitatav kliiniline jälgimine.
English: The full EPAR for Riprazo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Riprazo kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The recommended dose of Riprazo is 150 mg once a day.
Estonian: Riprazo soovituslik annus on 150 mg üks kord ööpäevas.
English: Riprazo has been studied in 14 main studies involving over 10,000 patients with essential hypertension.
Estonian: Riprazot uuriti 14 põhiuuringus, milles osales rohkem kui 10 000 essentsiaalse hüpertensiooniga patsienti.
English: Why has Riprazo been approved?
Estonian: Miks Riprazo heaks kiideti?
English: The CHMP therefore decided that the benefits of Riprazo are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seetõttu otsustas inimravimite komitee, et Riprazo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The European Commission granted a marketing authorisation valid throughout the European Union for
Estonian: Euroopa Komisjon andis Riprazo müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 22. augustil
English: This is a summary of the European public assessment report (EPAR) for Riprazo.
Estonian: See on ravimi Riprazo Euroopa avaliku hindamisaruande kokkuvõte.
English: How does Riprazo work?
Estonian: Kuidas Riprazo toimib?
English: When the results of the five studies comparing Riprazo taken alone with placebo were looked at together, patients aged under 65 years had an average fall in diastolic blood pressure of 9.0 mmHg after eight weeks of taking 150 mg Riprazo, from an average of 99.4 mmHg at the start of the study.
Estonian: Viie uuringu kokkuvõttes, milles võrreldi Riprazo kasutamist ainsa ravimina platseebo kasutamisega, vähenes alla 65 aasta vanuste patsientide diastoolne vererõhk pärast 150 mg Riprazo kasutamist kaheksa nädala jooksul keskmiselt 9,0 mm Hg võrra, võrreldes keskmise rõhuga 99,4 mm Hg ravi algul.
English: By blocking the production of angiotensin I, levels of both angiotensin I and angiotensin II fall.
Estonian: Angiotensiin I tekke blokeerimisega väheneb nii angiotensiin I kui ka angiotensiin II sisaldus.
English: It is available as tablets (150 and
Estonian: Seda turustatakse tablettidena (150 mg ja 300 mg).
English: Riprazo is a medicine that contains the active substance aliskiren.
Estonian: Riprazo on ravim, mis sisaldab toimeainena aliskireeni.
English: For the full list of all side effects reported with Riprazo, see the package leaflet.
Estonian: Riprazo kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: For more information about treatment with Riprazo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Riprazoga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Riprazo also reduced blood pressure in patients with diabetes and patients who were overweight.
Estonian: Riprazo vähendas vererõhku ka diabeediga või ülekaalulistel patsientidel.
English: What is the risk associated with Riprazo?
Estonian: Mis riskid Riprazoga kaasnevad?
English: The active substance in Riprazo, aliskiren, is a renin inhibitor.
Estonian: Riprazo toimeaine aliskireen on reniini inhibiitor.
English: What benefit has Riprazo shown during the studies?
Estonian: Milles seisneb uuringute põhjal Riprazo kasulikkus?
English: The studies with Riprazo in combination with other medicines showed additional decreases in blood pressure compared with the decreases produced by these medicines alone.
Estonian: Koos teiste ravimitega kasutatud Riprazo uuringud näitasid vererõhu lisavähenemist võrreldes sellega, kui samu ravimeid kasutati üksi.
English: It must not be used in patients who have had angioedema (swelling under the skin) with aliskiren, hereditary angioedema or angioedema of no obvious cause, or in women who are more than three months pregnant.
Estonian: Seda ei tohi kasutada patsientidel, kellel on olnud aliskireeni kasutamisel angioödeem (nahaalune paistetus), pärilik angioödeem või teadmata põhjusega angioödeem, ega rasedatel pärast esimest kolme raseduskuud.
English: Riprazo, taken alone or in combination with other medicines, was also compared with other medicines for hypertension.
Estonian: Riprazo kasutamist ainsa ravimina või koos teiste ravimitega võrreldi ka teiste kõrgvererõhuravimitega.
English: The studies lasted between six and 52 weeks and the main measure of effectiveness was the change in blood pressure during either the resting phase of the heartbeat (‘diastolic') or when the chambers of the heart were contracting (‘systolic').
Estonian: Uuringute kestus oli 6-52 nädalat ja efektiivsuse põhinäitaja oli diastoolse (nn alumise) või süstoolse (nn ülemise) vererõhu muutus.
English: The most common side effects with Riprazo (seen in between 1 and 10 patients in 100) are dizziness, diarrhoea, arthralgia (joint pain) and hyperkalaemia (high blood potassium levels).
Estonian: Riprazo kõige sagedam kõrvalnäht (esinenud 1-10 patsiendil 100st) on peapööritus, kõhulahtisus, artralgia (liigesevalu) ja hüperkaleemia (kaaliumi suur sisaldus veres).
English: Riprazo is used to treat essential hypertension (high blood pressure) in adults.
Estonian: Riprazot kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) ravimiseks täiskasvanud patsientidel.
English: Combination studies looked at Riprazo used with an ACE inhibitor (ramipril), an ARB (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a diuretic (hydrochlorothiazide).
Estonian: Ravimikombinatsioonide uuringutes vaadeldi Riprazo kasutamist koos ACEinhibiitoriga (ramipriil), ARB-ga (valsartaan), beetablokaatoriga (atenolool), kaltsiumikanalit blokeeriva ainega (amlodipiin) ja diureetikumiga (hüdroklorotiasiid).
English: Riprazo must also not be taken with ciclosporin, itraconazole or other medicines known as ‘potent P-glycoprotein inhibitors' (such as quinidine).
Estonian: Riprazot ei tohi manustada ka koos tsüklosporiiniga, itrakonasooliga või teiste ravimitega, mis on tugevad P-gp inhibiitorid (nt kinidiin).
English: In five of the studies, the effects of Riprazo taken alone were compared with those of placebo (a dummy treatment).
Estonian: Viies uuringus võrreldi ainsa ravimina kasutatud Riprazot platseeboga (näiv ravim).
English: Riprazo must not be used by people who are hypersensitive (allergic) to aliskiren or any of the other ingredients.
Estonian: Riprazot ei tohi kasutada patsiendid, kes on aliskireeni või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: It should be taken with a light meal preferably at the same time each day, but grapefruit juice should not be taken together with Riprazo.
Estonian: Seda manustatakse koos kerge einega, eelistatavalt iga päev samal kellaajal.
English: Riprazo may be taken alone or in combination with other medicines for hypertension, with the exception of ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) in patients with diabetes, or moderate or severe kidney impairment.
Estonian: Riprazot tohib võtta ainsa ravimina või koos teiste kõrgvererõhuravimitega, v.a angiotensiini muundava ensüümi (ACE) inhibiitoritega või angiotensiini retseptori blokaatoritega (ARB), kui patsiendil on diabeet või mõõdukas kuni raske neerukahjustus.
English: Riprazo in combination with an ACE inhibitor or an ARB must not be used in patients with diabetes, or moderate or severe kidney impairment.
Estonian: Riprazot ei tohi kasutada koos ACE-inhibiitoriga või ARB-ga, kui patsiendil on diabeet või mõõdukas kuni raske neeruhaigus.
English: This was compared with a fall of 5.8 mmHg from 99.3 mmHg in the patients
Estonian: Sellega võrreldes vähenes platseebot kasutanud patsientide vererõhk (ravi algul keskmiselt 99,3 mm Hg) 5,8 mm Hg võrra.
English: Larger falls were seen in patients aged 65 years or over and those taking higher doses of Riprazo.
Estonian: Vähemalt 65-aastastel patsientidel ja Riprazot suuremates annustes kasutanud patsientidel vähenes vererõhk rohkem.
English: The medicine can only be obtained with a prescription.
Estonian: Riprazo on retseptiravim.
English: Riprazo on its own was more effective than placebo and as effective as comparator treatments in reducing blood pressure.
Estonian: Riprazo vähendas kasutamisel ainsa ravimina vererõhku efektiivsemini kui platseebo ja sama efektiivselt kui võrdlusravimid.
English: However, in February 2012, following the review of a study called ALTITUDE, the CHMP recommended that Riprazo should not be used together with an ACE inhibitor or ARB in patients with diabetes or with moderate or severe kidney impairment because of an increase in the risk of cardiovascular and kidney problems.
Estonian: tulemuste läbivaatamist soovitas inimravimite komitee Riprazot mitte kasutada koos ACE-inhibiitoriga või ARB-ga patsientidel, kellel on diabeet või mõõdukas kuni raske neerukahjustus, sest ravim suurendab kardiovaskulaarsete ja neeruhäirete riski.
English: The CHMP noted that Riprazo is effective in reducing blood pressure when used alone or in combination.
Estonian: Inimravimite komitee märkis, et Riprazo on vererõhu alandamisel efektiivne ainuravimina või koos teiste ravimitega.
English: The dose of Riprazo may be increased to 300 mg once a day in patients whose blood pressure is not adequately controlled.
Estonian: Patsientidel, kelle vererõhk ei allu ravile piisavalt, võib Riprazo annust suurendada annuseni 300 mg üks kord ööpäevas.
English: The European Commission granted a marketing authorisation valid throughout the EU for Tevagrastim to Teva Generics GmbH on 15 September 2008.
Estonian: Euroopa Komisjon väljastas Tevagrastimi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Teva Generics GmbH 15. septembril 2008.
English: This means that Tevagrastim is similar to a biological medicine that is already authorised in the European Union (EU) and contains the same active substance (also known as the ‘reference medicine').
Estonian: See tähendab, et Tevagrastim on sarnane bioloogilise ravimiga, millel on juba Euroopa Liidus müügiluba ning mis sisaldab sama toimeainet (nimetatakse ka võrdlusravimiks).
English: To study the safety of Tevagrastim, two further studies were carried out in patients with lung cancer and with non-Hodgkin's lymphoma.
Estonian: Tevagrastimi ohutuse uurimiseks viidi läbi veel kaks täiendavat uuringut patsientidel, kellel oli kopsuvähk ja mitte-Hodgkini lümfoom.
English: How it is given, the dose and the duration of treatment depend on why it is being used, the patient's body weight and the response to treatment.
Estonian: Manustamisviis, annus ja ravi kestus olenevad kasutamise eesmärgist, patsiendi kehakaalust ja ravivastusest.
English: The Committee recommended that Tevagrastim be given marketing authorisation.
Estonian: Komitee soovitas anda Tevagrastimile müügiloa.
English: During the first 21-day chemotherapy cycle, patients treated with either Tevagrastim or Neupogen had severe neutropenia for an average of 1.1 days, compared with 3.8 days in those receiving placebo.
Estonian: Esimese 21-päevase keemiaravitsükli jooksul oli kas Tevagrastimiga või Neupogeniga ravitud patsientidel raske neutropeenia keskmiselt 1,1 päeva võrreldes 3,8 päevaga neil patsientidel, kes said platseebot.
English: Tevagrastim can also be used in patients who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.
Estonian: Lisaks võib Tevagrastimit kasutada patsientidel, kes hakkavad loovutama siirdamiseks vere tüvirakke, et aidata nendel rakkudel luuüdist vabaneda.
English: Tevagrastim is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately.
Estonian: Tevagrastimit manustatakse tavaliselt spetsiaalses ravikeskuses, kuigi patsiendid, kellele seda manustatakse nahaaluse süstena, võivad pärast asjakohase väljaõppe saamist süstida end ise.
English: Tevagrastim should not be used in people who may be hypersensitive (allergic) to filgrastim or any of the other ingredients.
Estonian: Tevagrastimit ei tohi kasutada patsiendid, kes võivad olla ülitundlikud (allergilised) filgrastiimi või selle ravimi mis tahes muu koostisaine suhtes.
English: Other side effects may be seen in more than 1 patient in 10, depending on the condition that Tevagrastim is being used for.
Estonian: Muud kõrvalnähud võivad esineda enam kui ühel patsiendil kümnest olenevalt haigusseisundist, mille ravimiseks Tevagrastimit kasutatakse.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Tevagrastim has been shown to have a comparable quality, safety and efficacy profile to Neupogen.
Estonian: Inimravimikomitee jõudis otsusele, et Euroopa Liidu nõuete kohaselt on tõendatud, et Tevagrastimi kvaliteedi, ohutuse ja tõhususe profiil on samaväärne Neupogeni omaga.
English: Tevagrastim was compared to Neupogen and to placebo (a dummy treatment) in one main study involving 348 patients with breast cancer.
Estonian: Tevagrastimit võrreldi Neupogeniga ja platseeboga (näiv ravim) ühes põhiuuringus, kus osales 348 rinnavähiga patsienti.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) TEVAGRASTIM EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE TEVAGRASTIM Kokkuvõte üldsusele
English: The active substance in Tevagrastim, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G-CSF).
Estonian: Tevagrastimi toimeaine filgrastiim on väga sarnane inimvalguga, mida nimetatakse granülotsüütide kolooniaid stimuleerivaks teguriks (G-CSF).
English: Filgrastim is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce filgrastim.
Estonian: Filgrastiimi toodetakse rekombinant-DNA-tehnika abil: seda toodab bakter, millele on lisatud filgrastiimi teket võimaldav geen (DNA).
English: The replacement acts in same way as naturally produced G-CSF by encouraging the bone marrow to produce more white blood cells.
Estonian: Tehislik G-CSF toimib samal viisil kui looduslikult tekkiv G-CSF, ergutades luuüdi tootma rohkem valgeliblesid.
English: Treatment with Tevagrastim and Neupogen brought about similar reductions in duration of severe neutropenia.
Estonian: Ravi Tevagrastimiga ja ravi Neupogeniga vähendasid raske neutropeenia kestust sarnasel määral.
English: Therefore, the CHMP's view was that, as for Neupogen, the benefit outweighs the identified risk.
Estonian: Seetõttu leidis inimravimikomitee, et nagu ka Neupogeni puhul, ületab Tevagrastimist saadav kasulikkus ilmnenud riskid.
English: Tevagrastim is used to stimulate the production of white blood cells in the following situations:
Estonian: Tevagrastimit kasutatakse valgeliblede tekkimise stimuleerimiseks järgmistel juhtudel:
English: For more information on biosimilar medicines, see the question-and-answer document here.
Estonian: Lisateavet bioloogiliselt sarnaste ravimite kohta saab teabedokumendist siit.
English: Therefore, the effectiveness of Tevagrastim was shown to be equivalent to that of Neupogen.
Estonian: Seega tõendati, et Tevagrastimi efektiivsus on samaväärne Neupogeni efektiivsusega.
English: What is the risk associated with Tevagrastim?
Estonian: Mis riskid Tevagrastimiga kaasnevad?
English: The most common side effect with Tevagrastim (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones).
Estonian: Tevagrastimi kõige sagedam kõrvalnäht (esinenud enam kui ühel patsiendil kümnest) on luulihaskonna valu.
English: Other information about Tevagrastim:
Estonian: Muu teave Tevagrastimi kohta
English: What is Tevagrastim?
Estonian: Mis on Tevagrastim?
English: Tevagrastim is a solution for injection or for infusion (drip into a vein).
Estonian: Tevagrastim on süstelahus või infusioonilahus (veeni tilgutatav lahus).
English: For the full list of all side effects reported with Tevagrastim, see the Package Leaflet.
Estonian: Tevagrastimi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: For more information, see the Package Leaflet.
Estonian: Täiendav teave on esitatud pakendi infolehel.
English: • to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy
Estonian: • neutropeenia (neutrofiilide ehk vere teatud valgeliblede sisalduse vähenemine) kestuse ja febriilse neutropeenia (palavikuga neutropeenia) esinemissageduse vähendamiseks tsütotoksilist (rakke hävitavat) keemiaravi (vähktõve ravi) saavatel patsientidel;
English: Why has Tevagrastim been approved?
Estonian: Miks Tevagrastim heaks kiideti?
English: Tevagrastim was studied to show that it is comparable to the reference medicine, Neupogen.
Estonian: Tevagrastimit uuriti selle ravimi samaväärsuse tõendamiseks võrdlusravimiga Neupogen.
English: infection, to reduce the risk of bacterial infections when other treatments are not appropriate.
Estonian: • püsiva neutropeenia raviks inimese immuunpuudulikkuse viiruse (HIV) kaugelearenenud nakkusega patsientidel bakteriaalsete nakkuste ohu vähendamiseks, kui muu ravi ei sobi.
English: Tevagrastim is given by injection under the skin or infusion into a vein.
Estonian: Tevagrastimit manustatakse nahaaluse süstega või infusiooniga veeni.
English: Tevagrastim is a ‘biosimilar' medicine.
Estonian: Tevagrastim on bioloogiliselt sarnane ravim.
English: The reference medicine for Tevagrastim is Neupogen.
Estonian: Tevagrastimi võrdlusravim on Neupogen.
English: What benefit has Tevagrastim shown during the studies?
Estonian: Milles seisneb uuringute põhjal Tevagrastimi kasulikkus?
English: How is Tevagrastim used?
Estonian: Kuidas Tevagrastimit kasutatakse?
English: How has Tevagrastim been studied?
Estonian: Kuidas Tevagrastimit uuriti?
English: • to increase levels of neutrophils and reduce the risk of infections in patients with neutropenia who have a history of severe, repeated infections;
Estonian: • neutrofiilide sisalduse suurendamiseks ja nakkuste ohu vähendamiseks neutropeeniaga patsientidel,
English: What is Tevagrastim used for?
Estonian: Milleks Tevagrastimit kasutatakse?
English: The full EPAR for Tevagrastim can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Tevagrastimi kohta leiate siit.
English: How does Tevagrastim work?
Estonian: Kuidas Tevagrastim toimib?
English: Tremfya received a marketing authorisation valid throughout the EU on 10 November 2017.
Estonian: Tremfya on saanud müügiloa, mis kehtib kogu ELis, 10. novembril 2017.
English: A main measure of effectiveness was a reduction of at least 90% in PASI scores.
Estonian: Efektiivsuse põhinäitaja oli PASI-skooride vähemalt 90% vähenemine.
English: Tremfya (guselkumab)
Estonian: Tremfya (guselkumaab)
English: Further information on Tremfya can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Tremfya kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Tremfya?
Estonian: Mis meetmed võetakse, et tagada Tremfya ohutu ja efektiivne kasutamine?
English: The recommended dose is 100 mg as a single dose, followed by a further dose after 4 weeks and then 100 mg every 8 weeks.
Estonian: Soovitatav annus on 100 mg ühekordse annusena, millele järgneb teine annus 4 nädala järel ja seejärel 100 mg annus iga 8 nädala järel.
English: Patients are likely to continue treatment with Tremfya because it is injected every 8 weeks (after the first 4 weeks) and patients can inject it themselves, making it convenient to use.
Estonian: Patsientidel on suur tõenäosus ravi Tremfyaga jätkata, sest seda süstitakse iga 8 nädala järel (pärast esimest 4 nädalat) ja patsiendid saavad ravimit ise süstida, mis tagab kasutusmugavuse.
English: After 16 weeks, about 71% of patients (588 out of 825) receiving Tremfya had a reduction of at least 90% in PASI scores, compared with 48% (282 out of 582) of those receiving adalimumab and under 3% (11 out of 422) receiving placebo.
Estonian: 16 nädala järel oli patsiente, kelle PASI-skoorid olid vähenenud vähemalt 90% võrra, Tremfya uuringurühmas 71% (588 patsienti 825st), adalimumaabi uuringurühmas 48% (282 patsienti 582st) ja platseeborühmas alla 3% (11 patsienti 422st).
English: Other information about Tremfya
Estonian: Muu teave Tremfya kohta
English: The Agency considered that Tremfya is effective and longer-term studies have shown that it remains effective with continued use.
Estonian: Amet järeldas, et Tremfya on efektiivne, ning pikemaajalised uuringud on tõendanud efektiivsuse püsimist pideval kasutamisel.
English: As for all medicines, data on the use of Tremfya are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Tremfya kasutamise kohta pidevat järelevalvet.
English: Tremfya must not be used in patients who have an ongoing infection that the doctor considers important.
Estonian: Tremfyat ei tohi kasutada patsiendid, kellel on aktiivne infektsioon, mida arst peab oluliseks.
English: After training, patients may inject Tremfya themselves if the doctor considers it appropriate.
Estonian: Pärast asjakohase väljaõppe saamist tohivad patsiendid süstida Tremfyat ise, kui arst peab seda asjakohaseks.
English: Patients whose psoriasis did not improve sufficiently after 16 weeks either received Tremfya or continued treatment with ustekinumab for at least 24 weeks.
Estonian: Patsiendid, kelle psoriaas ei olnud 16 nädala järel piisavalt paranenud, hakkasid kasutama Tremfyat või jätkasid ravi ustekinumaabiga vähemalt 24 nädalat.
English: Interleukin 23 is a messenger substance that controls the growth and maturation of some types of T cells.
Estonian: Interleukiin-23 on virgatsaine, mis reguleerib teatud tüüpi T-rakkude kasvu ja arengut.
English: What is Tremfya and what is it used for?
Estonian: Mis on Tremfya ja milleks seda kasutatakse?